Evidence map›Paper›PMID 36510377›Full record

ArticleJournal of clinical laboratory analysis2023

Long non-coding RNA HOXC-AS1 exerts its oncogenic effects in esophageal squamous cell carcinoma by interaction with IGF2BP2 to stabilize SIRT1 expression.

Zhengwu Yang, Junhu Wan, Liwei Ma, Zhuofang Li, Ruotong Yang, Haijun Yang, Junkuo Li, Fuyou Zhou, Liang Ming

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical laboratory analysis, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Epigenomics · 2024
    Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Zhengwu YangDepartment of Clinical Laboratory, The First Affiliated Hospital of Zhengzhou University, and the Key Clinical Laboratory of Henan Province, Henan, China.ORCID https://orcid.org/0000-0002-4051-014X
Junhu WanDepartment of Clinical Laboratory, The First Affiliated Hospital of Zhengzhou University, and the Key Clinical Laboratory of Henan Province, Henan, China.
Liwei MaDepartment of Clinical Laboratory, The First Affiliated Hospital of Zhengzhou University, and the Key Clinical Laboratory of Henan Province, Henan, China.
Zhuofang LiDepartment of Clinical Laboratory, The First Affiliated Hospital of Zhengzhou University, and the Key Clinical Laboratory of Henan Province, Henan, China.
Ruotong YangDepartment of Clinical Laboratory, The First Affiliated Hospital of Zhengzhou University, and the Key Clinical Laboratory of Henan Province, Henan, China.
Haijun YangHenan Key Medical Laboratory of Precise Prevention and Treatment of Esophageal Cancer, Anyang, China.
Junkuo LiDepartment of Pathology, Anyang Cancer Hospital, The Forth Affiliated Hospital of Henan University of Science and Technology, Henan, China.
Fuyou ZhouThoracic Department, Anyang Tumor Hospital, Henan Key Medical Laboratory of Precise Prevention and Treatment of Esophageal Cancer, Anyang, China.
Liang MingDepartment of Clinical Laboratory, The First Affiliated Hospital of Zhengzhou University, and the Key Clinical Laboratory of Henan Province, Henan, China.ORCID https://orcid.org/0000-0002-3622-3965
First Affiliated Hospital of Henan University · CNAnyang Tumor Hospital · CNHenan University of Science and Technology · CN

Funding

Key scientific research project plan of colleges and universities in Henan Province 22A320074Medical Science and Technology Provincial and Ministerial Co-construction Project of Henan province SBGJ202102131Medical Science and Technology Provincial and Ministerial Co-construction Project of Henan province SBGJ202102133Medical Science and Technology Research Project of Henan Province SBGJ202102139National Natural Science Foundation of China 82172351National Natural Science Foundation of China 82173018Natural Science Foundation of Henan Province 212300410395Young and Middle-aged Health Science and Technology Innovation Talents Project of Henan province YXKC2021036
6 · The paper itself

Abstract

backgroundLong non-coding RNA HOXC cluster antisense RNA 1 (HOXC-AS1) is a novel lncRNA whose cancer-promoting effect in gastric cancer and nasopharyngeal carcinoma has already been demonstrated. However, its functions in esophageal squamous cell carcinoma (ESCC) remains unknown. LncRNAs can interact with RNA-binding proteins (RBPs) and affect gene expression levels through post-transcriptional regulation. Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) is a widely studied RBP, and sirtuin 1 also known as SIRT1 has been reported to be involved in cancer progression.

methodsEstablishment of in vivo models, HE and immunohistochemistry staining verified the oncogenic effect of HOXC-AS1. The interaction relationship between HOXC-AS1, IGF2BP2 and SIRT1 was verified by RNA pulldown and RNA immunoprecipitation (RIP) assay. Relative expression and stability changes of genes were detected by qPCR and actinomycin D experiments. Finally, the effect of HOXC-AS1-IGF2BP2-SIRT1 axis on ESCC was verified by rescue experiments.

resultsHOXC-AS1 is highly expressed in ESCC cells and plays oncogenic effects in vivo. qPCR showed the positive relationship between HOXC-AS1 and SIRT1 following HOXC-AS1 knockdown or overexpression. RNA-pulldown, mass spectrometry and RIP assay demonstrated that IGF2BP2 is an RBP downstream of HOXC-AS1. Then, RIP and qPCR showed that IGF2BP2 could bind to SIRT1 mRNA and knockdown IGF2BP2 resulted in decreased SIRT1 mRNA level. Finally, a series of rescue assay showed that the HOXC-AS1-IGF2BP2-SIRT1 axis can affect the function of ESCC.

conclusionLncRNA HOXC-AS1 acts as an oncogenic role in ESCC, which impacts ESCC progression by interaction with IGF2BP2 to stabilize SIRT1 expression.

Indexed as

Esophageal NeoplasmsEsophageal Squamous Cell CarcinomaMicroRNAsRNA, Long NoncodingCell Line, TumorCell ProliferationGene Expression Regulation, NeoplasticHumansRNA-Binding ProteinsRNA, MessengerSirtuin 1IGF2BP2 protein, humanMicroRNAsRNA-Binding ProteinsRNA, Long NoncodingRNA, MessengerSIRT1 protein, humanSirtuin 1ESCCHOXC-AS1IGF2BP2RNA binding proteinSIRT1

Identifiers

PMID36510377
PMCPMC9833966
OpenAlexW4311288898

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.